公开(公告)号：US5798349A

公开(公告)日：1998-08-25

申请号：US390591

申请日：1995-02-17

Applicant: Julia Levy ,  Joan W. Miller ,  Evangelos S. Gradoudas ,  Tayyaba Hasan ,  Ursula Schmidt-Erfurth

Inventor： Julia Levy ,  Joan W. Miller ,  Evangelos S. Gradoudas ,  Tayyaba Hasan ,  Ursula Schmidt-Erfurth

IPC: A61K41/00 ,  A61K49/00 ,  A61K31/555

CPC classification number: A61F9/008 ,  A61K31/409 ,  A61K31/555 ,  A61K41/0071 ,  A61K49/0036 ,  A61K49/0084 ,  A61K9/0019 ,  A61K9/1275 ,  Y10S514/912

Abstract: Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.

公开(公告)号：US08987219B1

公开(公告)日：2015-03-24

申请号：US12180433

申请日：2008-07-25

Applicant: Eirini Iliaki ,  Anthony P. Adamis ,  Joan W. Miller ,  Evangelos S. Gragoudas

Inventor： Eirini Iliaki ,  Anthony P. Adamis ,  Joan W. Miller ,  Evangelos S. Gragoudas

IPC: A61K48/00 ,  C07H21/02 ,  C07H21/04

CPC classification number: A61K31/7052 ,  A61K9/0048 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/2842 ,  C07K2317/76 ,  A61K2300/00

Abstract: The invention includes a method of treating an intraocular disorder in a mammal, the method comprising administering to the mammal a Very Late Antigen-4 (VLA-4) antagonist for the treatment of selected ocular disorders.

Abstract translation: 本发明包括治疗哺乳动物眼内障碍的方法，所述方法包括向哺乳动物施用非常晚期抗原-4（VLA-4）拮抗剂以治疗所选择的眼部疾病。

公开(公告)号：US20130137642A1

公开(公告)日：2013-05-30

申请号：US13642887

申请日：2011-04-23

Applicant: Demetrios Vavvas ,  Georgios Trichonas ,  Joan W. Miller ,  Yusuke Murakami

Inventor： Demetrios Vavvas ,  Georgios Trichonas ,  Joan W. Miller ,  Yusuke Murakami

IPC: A61K38/00 ,  A61K31/40 ,  A61K31/4178

CPC classification number: A61K38/05 ,  A61B3/028 ,  A61B5/4839 ,  A61F9/0008 ,  A61K9/0048 ,  A61K31/12 ,  A61K31/195 ,  A61K31/40 ,  A61K31/4155 ,  A61K31/416 ,  A61K31/4174 ,  A61K31/4178 ,  A61K31/519 ,  A61K38/005 ,  A61K38/06 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells and/or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and/or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

Abstract translation: 提供了用于维持患有眼部疾病的受试者中感光细胞和/或视网膜色素上皮细胞的活力的方法和组合物，包括例如年龄相关性黄斑变性（AMD）（例如，干性或新生血管性AMD），色素性视网膜炎 （RP）或视网膜脱离。 感光细胞和/或视网膜色素上皮细胞的活力可以通过单独给予坏死抑制剂或与凋亡抑制剂组合施用于具有眼睛状况的眼睛的受试者来保存。 组合物在施用时维持细胞的活力，从而使与眼部疾病相关的视力丧失或视力功能最小化。

公开(公告)号：US20120165383A1

公开(公告)日：2012-06-28

申请号：US13293748

申请日：2011-11-10

Applicant: Vassiliki Poulaki ,  Joan W. Miller

Inventor： Vassiliki Poulaki ,  Joan W. Miller

IPC: A61K31/395 ,  A61K31/4155 ,  A61P27/02 ,  A61K31/365

CPC classification number: A61K31/395 ,  A61K31/365 ,  A61K31/47

Abstract: The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors.

Abstract translation: 本发明提供了使用Hsp90抑制剂治疗受试者的葡萄膜炎的方法，试剂盒和组合物。

公开(公告)号：US20110159004A1

公开(公告)日：2011-06-30

申请号：US12862234

申请日：2010-08-24

Applicant: DAVID ZACKS ,  JOAN W. MILLER

Inventor： DAVID ZACKS ,  JOAN W. MILLER

IPC: A61K39/395 ,  A61K38/07 ,  A61K38/08 ,  A61K38/18 ,  A61K31/7088 ,  A61P27/02

CPC classification number: A61K39/3955 ,  A01N1/0226 ,  A61K31/7088 ,  A61K38/02 ,  A61K38/06 ,  A61K38/16 ,  A61K38/55

Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.

Abstract translation: 提供了用于维持视网膜脱离后感光细胞活力的方法和组合物。 可以通过向具有视网膜脱离的眼睛的哺乳动物施用凋亡抑制剂来保存感光细胞的活力。 细胞凋亡抑制剂维持光感受器细胞的活力，直到视网膜重新附着于下面的视网膜色素上皮和脉络膜。 治疗可以最大限度地减少由于视网膜脱离而导致的视力丧失。

公开(公告)号：US07125542B2

公开(公告)日：2006-10-24

申请号：US09780142

申请日：2001-02-09

Applicant: Joan W. Miller ,  Evangelos S. Gragoudas ,  Reem Z. Renno

Inventor： Joan W. Miller ,  Evangelos S. Gragoudas ,  Reem Z. Renno

IPC: A61K39/395 ,  A61K38/41 ,  A61K38/18 ,  A01N55/02

CPC classification number: A61K41/0057 ,  A61K38/10 ,  A61K38/484 ,  A61K41/0071 ,  A61K41/0076 ,  A61K45/06 ,  A61K47/64 ,  A61K47/6849 ,  A61N5/062 ,  A61K2300/00

Abstract: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.

公开(公告)号：US06610679B2

公开(公告)日：2003-08-26

申请号：US09824155

申请日：2001-04-02

Applicant: Joan W. Miller ,  Evangelos S. Gragoudas

Inventor： Joan W. Miller ,  Evangelos S. Gragoudas

IPC: A61K31555

CPC classification number: A61F9/008 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/409 ,  A61K31/555 ,  A61K41/0071 ,  A61K49/0036 ,  A61K49/0084 ,  Y10S514/912

Abstract: Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.

Abstract translation: 使用绿色卟啉作为光活性剂，优选作为脂质体组合物，对以不想要的新血管系统为特征的眼睛疾病的光动力疗法如年龄相关性黄斑变性是有效的。

公开(公告)号：US06225303B1

公开(公告)日：2001-05-01

申请号：US09347382

申请日：1999-07-06

Applicant: Joan W. Miller ,  Evangelos S. Gragoudas

Inventor： Joan W. Miller ,  Evangelos S. Gragoudas

IPC: A61K3133

CPC classification number: A61F9/008 ,  A61K9/0019 ,  A61K9/1275 ,  A61K31/409 ,  A61K31/555 ,  A61K41/0071 ,  A61K49/0036 ,  A61K49/0084 ,  Y10S514/912

Abstract: Photodynamic therapy of conditions of the eye characterized by unwanted neovasculature, such as age-related macular degeneration, is effective using green porphyrins as photoactive agents, preferably as liposomal compositions.

Abstract translation: 使用绿色卟啉作为光活性剂，优选作为脂质体组合物，对以不想要的新血管系统为特征的眼睛疾病的光动力疗法如年龄相关性黄斑变性是有效的。

公开(公告)号：US08658633B2

公开(公告)日：2014-02-25

申请号：US11654892

申请日：2007-01-18

Applicant: Vasiliki Poulaki ,  Joan W. Miller ,  Evangelos S. Gragoudas

Inventor： Vasiliki Poulaki ,  Joan W. Miller ,  Evangelos S. Gragoudas

IPC: A61K31/555

CPC classification number: A61K41/0057 ,  A61K31/395 ,  A61K41/0061 ,  A61K41/0071 ,  A61K41/0076 ,  A61K2300/00

Abstract: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an ansamycin analog or heat shock protein 90 inhibitor, for example, 17-allylamino-17-demethoxygeldanamycin.

Abstract translation: 提供了用于治疗特征在于存在不想要的脉络膜新血管的眼部病症的方法和组合物，例如新生血管性年龄相关性黄斑变性。 通过组合PDT与安莎霉素类似物或热休克蛋白90抑制剂，例如17-烯丙基氨基-17-去甲氧基格尔德霉素，可以提高例如基于光动力疗法（PDT）的方法的选择性和灵敏度。

公开(公告)号：US20140024598A1

公开(公告)日：2014-01-23

申请号：US13882932

申请日：2011-10-21

Applicant: Demetrios Vavvas ,  Joan W. Miller ,  Maki Kayama

Inventor： Demetrios Vavvas ,  Joan W. Miller ,  Maki Kayama

IPC: A61K31/4178 ,  A61K38/00

CPC classification number: A61K38/06 ,  A61K9/0048 ,  A61K31/195 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4166 ,  A61K31/4178 ,  A61K38/005 ,  A61K2300/00 ,  A61K31/401

Abstract: Provided are methods and compositions for maintaining the viability of retinal ganglion cells in a subject with an ocular disorder including, for example, glaucoma and optic nerve injury. The viability of the retinal ganglion cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells and/or promote axon regeneration, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

Abstract translation: 提供了用于维持具有眼部疾病（例如青光眼和视神经损伤）的受试者的视网膜神经节细胞的存活力的方法和组合物。 视网膜神经节细胞的活力可以通过单独给予坏死抑制剂或与凋亡抑制剂组合施用于具有眼睛状况的眼睛的受试者来保存。 组合物在施用时维持细胞的活力和/或促进轴突再生，从而使与眼部疾病相关的视力丧失或视觉功能最小化。